Kähkönen TE, Wen J, Yang R, Halleen JM 2025 Effects of standard-of-care therapies on tumor growth, tumor-induced bone loss and bone pain in preclinical models of breast and prostate cancer bone metastasis and multiple myeloma bone disease. Mol Cancer Ther 24 (10_Supplement):C122. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 22-26, 2025, Boston, MA. POSTER.
Kähkönen TE, Wen J, Yang R, Xu Y, Halleen JM 2025 Effects of zoledronic acid on tumor growth, tumor-induced bone loss and bone pain in preclinical models of breast and prostate cancer bone metastasis and multiple myeloma bone disease. J Bone Miner Res 40 (Supplement 1):SUN-100. ASBMR Annual Meeting, September 5-8, 2025, Seattle, WA. POSTER.
Kähkönen TE, Kim Y, Yeu J, Min S, Halleen JM 2025 Correlation analysis of small-animal DXA for bone parameters and total body, fat and lean mass. JBMR Plus 9 (Supplement_2):P025. ECTS Annual Meeting, May 23-26, Innsbruck, Austria. POSTER.
Kähkönen TE, Wen J, Yang R, Xu Y, Zhang M, Halleen JM 2025 Bone Metastasis Technology Platform© – Establishing clinically relevant bone metastasis models for breast and prostate cancer and multiple myeloma. Cancer Res 85 (8_Supplement_1):3927. AACR Annual Meeting, April 25-30, 2025, Chicago, IL. POSTER.
Kähkönen TE, Halleen JM 2024 Dual-energy x-ray absorptiometry (DXA) differentiates body composition and bone mineral density in different mouse strains. JBMR Plus 9 (Supplement_2):P026. ECTS Annual Meeting, May 25-28, 2024, Marseille, France. POSTER.
Kähkönen TE, Halleen JM, MacRitchie G, Andersson R, Bernoulli J 2024 Immunotherapy development landscape for bone metastasis – need of predictive preclinical efficacy evaluation for de-risking clinical development. Cancer Res 84 (6_Supplement):2815. AACR Annual Meeting, April 5 -10, 2024, San Diego, CA. POSTER.
Kähkönen TE, Halleen JM, Bernoulli J 2023 Preclinical Bone Metastasis Technology Platform – Predictive evaluation of Experimental Therapies on Bone Metastasis. Mol Cancer Ther 22 (12_Supplement):A007. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 11-15, 2023, Boston, MA. POSTER.
Kähkönen TE, Halleen JM, Kinoshita R, Morita S, Sagayama K, Sakaguchi M 2022 Neutralizing antibody for S100A8/A9 soil sensing signal to prevent metastatic disease. Eur J Cancer 174 (Supplement 1):S122. EORTC-NCI-AACR Symposium, October 26-28, 2022, Barcelona, Spain. POSTER.
Occhetta P, Piazza S, Kähkönen TE, Halleen JM, Visone R, Rasponi M 2022 A predictive human 3D cartilage-on-chip model for screening anti-osteoarthritis drugs and medical devices. ECTS Annual Meeting, May 6-10, 2022, Helsinki, Finland. POSTER.
Kähkönen TE, Halleen JM, Bernoulli J 2021 Identification of genetic signatures in bone metastasis of breast and prostate cancer. Cancer Res 82 (12_Supplement):5740. AACR Annual Meeting, April 8-13, 2022, New Orleans, LA. POSTER.
Occhetta P, Piazza S, Kähkönen TE, Halleen JM, Visone R, Rasponi M 2021 uKnee: a human osteoarthritic (OA) cartilage-on-chip model for efficacy screening of anti-OA drugs and medical devices. J Bone Miner Res 37 (Suppl 1):SUN-257. ASBMR Annual Meeting, online. POSTER.
Kähkönen TE, Halleen JM, Bernoulli J 2021 Limited data from clinical trials assessing immunotherapy effects on bone metastases. Cancer Res 81 (13_Supplement):2870. AACR Annual Meeting, online. POSTER.
If you are interested to learn more,
see our services or contact us directly.

